Analyst Ratings For Dicerna Pharmaceuticals
Dicerna Pharmaceuticals (NASDAQ:DRNA) has observed the following analyst ratings within the last quarter:
|Last 30 Days||1 Month Ago||2 Months Ago||3 Months Ago|
In the last 3 months, 7 analysts have offered 12-month price targets for Dicerna Pharmaceuticals. The company has an average price target of $39.0 with a high of $48.00 and a low of $30.00.
This current average has decreased by 10.96% from the previous average price target of $43.8.
Analyst Ratings: What Are They?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish “analyst ratings” for stocks. Analysts typically rate each stock once per quarter.
Analysts also give out recommendations like “buy”, “sell”, “hold”, or similar verbage for each stock based on their overall evaluations of the corres ponding company. A “buy” indicates that an analyst is optimistic about a stock’s short-term or mid-term growth, recommending traders to purchase the stock. Contrastingly, a “sell” means that an analyst believes the stock will trend downwards in that same time frame. A “hold” suggests that investors should not buy more of or sell any of the specified stock due to that analyst’s prediction of stagnation.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.